

CSD/BSE&NSE/BM/2020-21
February 20, 2021

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of the SEBI (LODR) Regulations, 2015

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company at its meeting held today i.e. 20th February, 2021 has *inter-alia* considered and approved the following:

1. Issuance of 1,81,00,000 (One Crore Eighty-One Lakh) fully Convertible Warrants on Preferential Basis to the Promoter/ Promoter Group (details as annexed) of the company in accordance with the provisions of the Companies Act, 2013, Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable statutory provisions and subject to the approval of shareholders in the Extra-Ordinary General Meeting of the Company;

The price at which the warrants will be issued shall be determined in accordance with provisions of chapter V of SEBI (Issue of capital and Disclosure Requirements) Regulations, 2018 as amended.

2. Notice convening the Extra-Ordinary General Meeting of the Company to be held on **Saturday, 20th March, 2021** seeking the approval of the Shareholders of the Company for the issuance of fully convertible warrants on preferential basis.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

The details as required under Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 are furnished in the Annexure forming part of this letter.

We request you to take the aforesaid information on your records. The Board Meeting commenced at 10:30 A.M. and concluded at 11:00 A.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**



Shrenik Soni
Company Secretary
Encl.: as above

Suven Life Sciences Limited

Preferential Issue

Sl. No.	Particulars	Details
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Warrants Convertible into Equity Shares
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment, etc.);	Preferential Allotment
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	1,81,00,000 number of convertible warrants
4.	Names of the investor;	<u>Promoter Group</u> Jasti Property And Equity Holdings Private Limited <i>(In its capacity as sole trustee of Jasti Family Trust)</i>

Suven Life Sciences Limited